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Abstract
Introduction: The pathology of ankylosing spondylitis (AS) suggests that certain cytokines and matrix
metalloproteinases (MMPs) might provide useful markers of disease activity. Serum levels of some cytokines and
MMPs have been found to be elevated in active disease, but there is a general lack of information about
biomarker profiles in AS and how these are related to disease activity and function. The purpose of this study was
to investigate whether clinical measures of disease activity and function in AS are associated with particular profiles
of circulating cytokines and MMPs.
Methods: Measurement of 30 cytokines, five MMPs and four tissue inhibitors of metalloproteinases was carried out
using Luminex® technology on a well-characterised population of AS patients (n = 157). The relationship between
biomarker levels and measures of disease activity (Bath ankylosing spondylitis disease activity index (BASDAI)),
function (Bath ankylosing spondylitis functional index) and global health (Bath ankylosing spondylitis global health)
was investigated. Principal component analysis was used to reduce the large number of biomarkers to a smaller
set of independent components, which were investigated for their association with clinical measures. Further
analyses were carried out using hierarchical clustering, multiple regression or multivariate logistic regression.
Results: Principal component analysis identified eight clusters consisting of various combinations of cytokines and
MMPs. The strongest association with the BASDAI was found with a component consisting of MMP-8, MMP-9,
hepatocyte growth factor and CXCL8, and was independent of C-reactive protein levels. This component was also
associated with current smoking. Hierarchical clustering revealed two distinct patient clusters that could be
separated on the basis of MMP levels. The high MMP cluster was associated with increased C-reactive protein, the
BASDAI and the Bath ankylosing spondylitis functional index.
Conclusions: A profile consisting of high levels of MMP-8, MMP-9, hepatocyte growth factor and CXCL8 is
associated with increased disease activity in AS. High MMP levels are also associated with smoking and worse
function in AS.
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
disease of the spine, three times more common in men
than in women. It is characterised by sacroiliitis, accom-
panied by inflammation of the entheses and the spine
[1]. Involvement of peripheral joints occurs in about
30% of patients. Extraskeletal manifestations include
acute anterior uveitis, inflammatory bowel symptoms
and renal, pulmonary and cardiac involvement.
Although genetic factors are important in disease devel-
opment, there is no clear way of predicting which
patients will suffer severe disease [2].
Standard measures of acute phase response (erythro-
cyte sedimentation rate/C-reactive protein (CRP)) are
not generally felt to be reliable indicators of activity of
spinal disease [3]: these measures correlate weakly with
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disease activity in AS, do not fully reflect the disease
process, and their value in clinical trials is limited.
Neither measure appears to be clearly superior in terms
of validity [3].
Although the serum levels of some cytokines and
matrix metalloproteinases (MMPs) have been found to
be elevated in active disease, there is a general lack of
information about biomarker profiles in AS and how
these are related to disease activity. Individual cytokines/
cytokine receptors that have been associated with dis-
ease activity in AS include IL-6, transforming growth
factor beta-1, vascular endothelial growth factor (VEGF),
macrophage colony-stimulating factor and soluble IL-2
receptor [4-9]. Reductions in the circulating levels of
transforming growth factor beta-1, IL-6, VEGF and
macrophage colony-stimulating factor have been seen in
patients treated with TNF inhibitors [10-14], although
not all studies have shown changes after anti-TNF treat-
ment [9,15].
Recent studies have suggested that serum MMP-3 is a
useful marker of disease activity in AS, particularly in
patients with peripheral synovitis [9,16,17]. A number of
studies have shown that MMP-3 levels are reduced in
response to TNF antagonists, although its usefulness as
a marker of response is debatable [9,13,16,18-22]. A
recent study has suggested that MMP-3 levels were not
useful for monitoring and predicting response to etaner-
cept in terms of disease activity and functional assess-
ments [22]. However, higher levels of MMP-3 have been
shown to be predictive of greater radiographic progres-
sion in AS, especially in patients with pre-existing
damage [23].
Clinical disease activity and particular disease features
in AS will possibly be associated with discrete cytokine
profiles, and combinations of cytokines and associated
markers (for example, MMPs) may be more informative
than individual markers. With the availability of technol-
ogy for measuring many different biomarkers simulta-
neously from small serum samples, we have carried out
an investigation of the relationship between a large
panel of cytokines/MMPs/tissue inhibitors of metallo-
proteinases (TIMPs) and disease activity in a well-char-
acterised population of patients with established AS.
Materials and methods
Patients with AS (n = 180) were recruited from six sec-
ondary care rheumatology centres in the UK (Bath,
North Bristol, Cannock, Durham, Romford and Stoke-
on-Trent). Patients invited to take part in the study
were over 21 years of age, had AS according to the
modified New York Criteria of 1984 [24], and provided
written informed consent according to the declaration
of Helsinki. The Trent Research Ethics Committee and
the six site-specific National Health Service trusts
approved the multicentre study. The majority of patients
had been on a stable dose of nonsteroidal anti-inflam-
matory drugs for at least the previous 3 months.
Patients on anti-TNF therapy, systemic steroid use in
the previous 3 months or bisphosphonates in the pre-
vious 12 months were excluded from the study. Other
exclusions included current use of methotrexate, sulfasa-
lazine, raloxifene, calcitonin, phenylbutazone or hor-
mone replacement therapy.
The principal aim of this study was to evaluate the
effect of bisphosphonate (alendronate) on global health
(Bath ankylosing spondylitis global health (BAS-G)) in
AS (Bisphosphonates in Ankylosing Spondylitis trial).
Secondary aims were to determine whether there were
changes in disease activity, function and bone status,
and whether changes in biomarker levels were different
between patients treated with or without alendronate. A
preliminary report has been published, which indicated
that alendronate had no significant effect on changes in
CRP, cytokine and MMP levels [25]. A further aim of
the study was to investigate the relationship between
circulating biomarker levels and measures of disease
activity and function in AS patients on standard non-
steroidal anti-inflammatory drug therapy. Data collected
from the baseline visit are reported here.
Baseline assessment included questionnaires to assess
disease activity (Bath ankylosing spondylitis disease
activity index (BASDAI)), function (Bath ankylosing
spondylitis functional index (BASFI)) and well-being
(BAS-G). The BASDAI is based on six questions related
to fatigue, spinal pain, peripheral arthritis, enthesitis and
morning stiffness (both severity and duration). The
BASFI is a set of 10 questions that consider activities
related to functional anatomy and the patients’ ability to
cope with everyday life. The BAS-G consists of two
questions that assess the effect of the disease on the
patient’s well-being. A 10-cm visual analogue scale is
used to answer questions to the BASDAI, BASFI and
BAS-G. All measures are scored between 0 and 10, with
higher values indicating worse disease activity, function
or well-being.
Blood samples were taken for measurement of cyto-
kines, MMPs and TIMPs, as well as a full blood count,
urea and electrolyte levels, serum calcium and CRP.
Information was also collected on smoking status, smok-
ing duration, average number of cigarettes smoked per
day and age of smoking cessation. Pack years were cal-
culated (1 pack year = 20 cigarettes/day for 1 year) to
provide a quantitative measure of smoking history. The
effects of smoking intensity were assessed by categoris-
ing participants according to pack-year history, as in
previous studies in AS [26]: category 1, 0 pack years;
category 2, 1 to 15 pack years; category 3, 16 to 30 pack
years; and category 4, > 30 pack years.
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Measurement of cytokines, MMPs and TIMPs
Sera were separated from bloods collected in plain Bec-
ton Dickinson Vacutainer® tubes (Becton Dickinson,
Oxford, Oxfordshire, UK) at study entry. All sera were
stored at -70°C until required. Measurement of the var-
ious cytokines, MMPs and TIMPs was performed using
multiplex, bead-based (Luminex®) assays on a Bio-
Plex™ 200 suspension array system (Bio-Rad Labora-
tories, Hemel Hempstead, Hertfordshire, UK). The levels
of 30 cytokines (Human cytokine 30-plex panel; Life
Technologies, Paisley, UK), five MMPs and four TIMPS
(Fluorokine multi-analyte MMP and TIMP kits; R&D
Systems Europe, Abingdon, UK) were measured in sepa-
rate multiplex assays according to the manufacturers’
instructions. The following biomarkers were measured:
cytokines and cytokine receptors - IL-1b, IL-1 receptor
antagonist, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-10, IL-
12p70, IL-13, IL-15, IL-17, IFNa, IFNg, TNFa, epider-
mal growth factor, basic fibroblast growth factor, VEGF,
hepatocyte growth factor (HGF), granulocyte colony-sti-
mulating factor and granulocyte-macrophage colony-sti-
mulating factor; chemokines - CXCL8, CXCL10,
Eotaxin, macrophage inflammatory protein-1a (CCL3),
macrophage inflammatory protein-1b (CCL4), monokine
induced by gamma interferon (CXCL9), monocyte che-
motactic protein-1(CCL2) and regulated upon activation,
normal T-cell expressed, and secreted (CCL5); MMPs -
MMP-1, MMP-2, MMP-3, MMP-8 and MMP-9; and
TIMPs - TIMP-1, TIMP-2, TIMP-3 and TIMP-4. High
and low control samples were used in each assay. To
test the reproducibility of MMP measurements we also
measured the same samples using standard ELISA kits
for MMP-3 and MMP-8 (R&D Systems).
Statistical analysis
All data were tested for normality and the appropriate
parametric or nonparametric tests were selected. Con-
tinuous data were expressed as mean ± standard devia-
tion or median (interquartile range), as appropriate.
Univariate correlations between biomarker levels and
disease measures were carried out using Spearman’s cor-
relation. A multivariate variable selection procedure
using the algorithm of McHenry [27] was initially used
to select cytokine, MMP or TIMP variables that showed
the strongest association with each clinical assessment.
Multiple regression analysis or multivariate logistic
regression analysis were used to investigate the associa-
tion between clinical measures and biomarker levels
while adjusting for other possible confounders. Where
appropriate, data transformation to normality (log or
square-root transformation) was carried out before ana-
lysis. When cytokine levels were below the level of
detection, we carried out imputation of the lowest stan-
dard for that particular cytokine [28].
Principal component analysis
Principal component analysis (PCA) is an exploratory
technique that reduces the dimensionality of a large
number of variables to a smaller set of uncorrelated
independent components, and allows the identification
of combinations of variables that best explain the differ-
ences between observations. PCA allows the identifica-
tion of patterns within the variables and expresses them
in a way that highlights the similarities and differences
between them. Principal components (PCs) were
extracted using varimax rotation, with the factor selec-
tion based on an eigenvalue cutoff of 1.0. The PCs iden-
tified were used in multivariate analysis to look for
associations with clinical measures.
Hierarchical cluster analysis
Biomarker levels were first converted to log2 and
expressed relative to the normalised mean value. These
measurements were used to generate heat maps using
Genesis software (version 1.7.2; Alexander Sturn, Insti-
tute for Genomics and Bioinformatics, Graz University
of Technology, Graz, Austria). The Genesis program
uses a hierarchical clustering method that enables
groups of variables with similar expression levels to be
clustered together, as well as grouping together patient
samples with similar expression patterns.
Statistical analyses were carried out using Number
Cruncher Statistical Software package for Windows
(Number Cruncher Statistical System 2000; NCSS Statis-
tical Software, Kaysville, UT, USA). The significance
level was set at P = 0.05.
Results
Characteristics of the ankylosing spondylitis patients
Table 1 displays the demographic and clinical character-
istics of the 180 AS subjects from the six centres
involved in the study. Serum samples were available on
Table 1 Demographic and clinical characteristics of the
ankylosing spondylitis patients at baseline
Variable All patients (n = 180) Biomarker study (n = 157)
Age (years) 48.7 (37.0 to 56.5) 49.05 (38.3 to 57.7)
Duration (years) 18.0 (10.0 to 31.0) 18.0 (11.0 to 31.0)
Male 147/180 (81.7%) 130/157 (82.8%)
CRP (mg/dl) 7.9 (5.0 to 15.0) 7.0 (5.0 to 15.0)
BASDAI 4.04 (2.29 to 5.77) 4.00 (2.18 to 5.76)
BASFI 3.30 (1.80 to 5.38) 3.33 (1.78 to 5.43)
BASG 4.25 (2.12 to 6.20) 4.10 (2.15 to 6.20)
Ever smoked 106/180 (58.9%) 95/157 (63.8%)
Current smoker 47/180 (26.1%) 40/157 (25.5%)
Values are median (interquartile range) unless otherwise stated. BASDAI, Bath
ankylosing spondylitis disease activity index; BASFI, Bath ankylosing
spondylitis functional index; BAS-G, Bath ankylosing spondylitis global health;
CRP, C-reactive protein.
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157 patients at baseline. No difference was found in
clinical disease measures between patients with and
without serum samples available. Information on smok-
ing status (never, past, current) was available for all
patients investigated, although the pack-year history was
only obtained for 68/96 (70.8%) of patients who had
smoked.
Correlation between serum biomarkers and clinical
disease measures at baseline
Variables showing significant correlations (Spearman)
are shown in Additional File 1. Baseline CRP levels cor-
related significantly with baseline levels of IL-6 (r =
0.25, P = 0.004), MMP-1 (r = 0.17, P = 0.04), MMP-2 (r
= 0.17, P = 0.04), MMP-3 (r = 0.24, P = 0.002), MMP-8
(r = 0.23, P = 0.003) and MMP-9 (r = 0.23, P = 0.003).
Baseline CRP was correlated with the BASFI (r = 0.19, P
= 0.01) but not the BASDAI or BAS-G, and no correla-
tion was found between IL-6 levels and the BASDAI,
BASFI or BAS-G. Significant correlations with all three
clinical assessments were found, however, for HGF and
MMP-8 levels (r ≥ 0.20, P ≥ 0.02). For the BASDAI, sig-
nificant correlations were also found with CXCL10 (r =
0.17, P = 0.04) and MMP-9 levels (r = 0.24, P = 0.002).
MMP-9 levels were also correlated with the BASFI (r =
0.17, P = 0.03), while MMP-1 levels were correlated
with both the BASFI and BAS-G (r = 0.20, P = 0.01 and
r = 0.19, P = 0.01, respectively).
The reproducibility of MMP-3 and MMP-8 correla-
tions with clinical measures was tested by also measur-
ing these MMPs using standard ELISA kits (R&D
Systems). The results were similar to those achieved
using the Luminex® system. MMP-3 levels were corre-
lated with CRP levels but not with the BASDAI, BASFI
or BAS-G. MMP-8 levels were significantly correlated
with CRP and all three clinical assessments (Additional
file 2).
Multivariate analyses
A multivariate variable selection procedure was initially
used to select cytokine, MMP or TIMP variables that
showed the strongest association with each clinical
assessment. To further determine which variables were
independently associated with clinical measures we then
carried out multiple regression analyses for each clinical
assessment (dependent variable) in models that were
adjusted for age, sex and disease duration, and included
all significant variables found in the preliminary
analyses.
Associations with C-reactive protein
MMP-2, MMP-3 and MMP-8 levels were found to be
independently associated with the CRP level (log trans-
formed) at baseline (Table 2). MMP-3 and MMP-8 were
positively associated while MMP-2 showed a negative
association. No association of IL-6 or any other cyto-
kine, MMP or TIMP was found in this model. Adjust-
ment for age, sex and disease duration made little or no
difference to the association of CRP levels with MMP
levels. A similar model of association was found when
MMP-3 and MMP-8 levels measured by ELISA replaced
those obtained by Luminex® analysis (data not shown).
Associations with the BASDAI
Female sex and MMP-8 levels provided the best model
for association with the BASDAI (square root trans-
formed) at baseline (Table 3, Model 1), although a very
similar model was found with female sex and MMP-9
levels as independent variables (Additional file 3).
MMP-8 and MMP-9 levels were not independently
associated since both lost significance in models con-
taining both MMPs as independent variables. CRP was
independently associated in a model adjusted for female
sex only, but lost significance in models containing
MMP-8 or MMP-9 levels. No other MMP, TIMP or
cytokine were associated in these models. MMP-8 levels
measured by ELISA were also significantly associated
Table 2 Multiple regression analysis showing variables
associated with CRP levels in ankylosing spondylitis
patients at baseline
Response variable (CRP)a
Independent variable Regression coefficient (SE) P value
MMP-3 (pg/ml) 1.108 × 10-5 (2.335 × 10-6) 0.000005
MMP-8 (pg/ml) 4.189 × 10-6 (1.610 × 10-6) 0.010
MMP-2 (pg/ml) -2.277 × 10-6 (9.477 × 10-7) 0.018
SE, standard error. aC-reactive protein (CRP) levels were log transformed to
normality before analysis.
Table 3 Multiple regression models showing variables
associated with the BASDAI, BASFI and BAS-G at baseline
Response variablea
Independent variable Regression coefficient (SE) P value
Model 1 BASDAI
Female 0.302 (0.119) 0.012
MMP-8 (pg/ml) 6.667 × 10-6 (2.533 × 10-6) 0.009
CRP (mg/l) 0.005 (0.003) 0.054
Model 2 BASFI
Age 0.012 (0.004) 0.002
CRP (mg/dl) 0.011 (0.003) 0.001
Model 3 BAS-G
Female 0.314 (0.131) 0.018
MMP-8 (pg/ml) 6.548 × 10-6 (2.786 × 10-6) 0.020
CRP, C-reactive protein; MMP, matrix metalloproteinase; SE, standard error.
aFor each regression model, square root transformation of the response
variable - Bath ankylosing spondylitis disease activity index (BASDAI), Bath
ankylosing spondylitis functional index (BASFI) or Bath ankylosing spondylitis
global health (BAS-G) - was carried out to achieve a normal distribution of the
data.
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with the BASDAI in a model that also contained female
sex (data not shown).
Associations with the BASFI
The strongest association with the BASFI (square root
transformed) was found in a model containing age and
CRP levels as independent variables (Table 3, Model 2).
There were no independent associations of any cytokine,
MMP or TIMP with the BASFI in models that con-
tained CRP.
Associations with the BAS-G
As for the BASDAI, female sex and MMP-8 levels pro-
vided the strongest independent association with the
BAS-G (Table 3, Model 3). In this case, MMP-8 levels
remained independently associated in models that also
contained MMP-9 as a variable (Additional file 3). A
similar model was obtained when MMP-8 levels mea-
sured by ELISA replaced those obtained by Luminex®
analysis (data not shown). No association was found
with CRP levels, although this approached significance
(P = 0.07) in models that did not include MMP-8.
Principal component analysis
We carried out PCA to investigate patterns of cytokines
and MMPs in the data. This allowed the identification
of factors containing particular biomarker profiles,
which were examined for their association with clinical
assessments in AS. Eight PCs were identified, explaining
78.3% of the total variance. These PCs are shown in
Table 4 along with their respective factor loadings after
varimax rotation.
The only PC showing an association with any clinical
assessments was PC3, consisting of MMP-8, MMP-9,
CXCL8 and HGF (Table 4). This component was asso-
ciated with both CRP (log transformed) and the BAS-
DAI (square root transformed). The latter association
was independent of CRP, and remained significant after
adjustment for age, sex and disease duration (Table 5).
Interestingly, PC3 was also significantly higher in cur-
rent smokers than in past smokers (0.455 vs. 0.089, P =
0.004) or in patients who had never smoked (0.455 vs.
-0.350, P = 0.01). There was also a significant trend (P =
0.0005) of increasing PC3 level with increasing pack-
year category (Table 6). Analysis of the individual mar-
kers of the PC3 profile demonstrated that MMP-8 and
MMP-9 were both higher in current smokers than in
past or nonsmokers (Table 7). MMP-8 levels also
showed an increasing trend (P < 0.0001) with increasing
pack-year category, although no trend was seen with
MMP-9 levels (Additional file 4).
Hierarchical clustering analysis
Hierarchical cluster analysis was carried out on cyto-
kines, MMPs and TIMPS separately and in combination.
Heat maps generated from these analyses were used to
identify patient groups that clustered together according
to the similarity or dissimilarity of their profiles.
Discrimination between patient groups was best
achieved by hierarchical cluster analysis of the five
Table 4 Principal component analysis of serum biomarkers in ankylosing spondylitis patients at baseline
PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8
IL-15 (0.972) IFNg (0.955) MMP-8 (0.849) GM-CSF (0.913) CXCL10 (-0.676) MMP-2 (-0.700) bFGF (0.744) EGF (0.735)
IL-2 (0.970) IL-12 (0.936) MMP-9 (0.796) IL-10 (0.813) IL-13 (0.626) MMP-3 (-0.759) IL-1Ra (0.493) CXCL8 (0.436)
MIP-1b (0.930) IL-5 (0.842) CXCL8 (0.527) VEGF (0.437) MCP-1 (0.425)
IFNa (0.916) Eotaxin (0.760) HGF (0.453)
IL-1b (0.877) IL-2R (0.712)
TNFa (0.841) IL-17 (0.633)
MIP-1a (0.812) IL-4 (-0.565)
IL-7 (0.771) IL-13 (0.525)
IL-6 (0.736) MCP-1 (0.499)
MIG (0.722) VEGF (-0.477)
IL-1Ra (0.680) TNFa (0.408)
IL-17 (0.674)
IL-4 (0.673)
IL-2R (0.609)
GCSF (0.486)
HGF (0.462)
30.16%a 17.61%a 6.63%a 6.03%a 4.80%a 3.90%a 4.70%a 4.44%a
Biomarkers in each principal component are shown with factor loadings (brackets) after varimax rotation. bFGF, basic fibroblast growth factor; EGF, epidermal
growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HGF, hepatocyte growth factor; IL-1Ra,
IL-1 receptor antagonist; MCP-1, monocyte chemotactic protein-1; MIG, monokine induced by gamma interferon; MIP-1, macrophage inflammatory protein-1;
MMP, matrix metalloproteinase; PC, principal component; VEGF, vascular endothelial growth factor. aPercentage variance.
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MMPs alone. This resulted in clustering of two major
groups of patients based on relatively low or high MMP
levels (Figure 1). The high MMP group was charac-
terised by significantly higher levels of MMP-1 (20%
higher), MMP-3 (43% higher), MMP-8 (222% higher)
and MMP-9 (128% higher) (Additional file 5). There
was no difference in MMP-2 levels between the two
groups.
The high MMP group of patients had significantly
higher CRP levels (median 12.0 vs. 6.0, P = 0.001),
higher BASDAI scores (median, 4.67 vs. 3.27, P = 0.006)
and higher BASFI scores (median, 3.83 vs. 2.94, P =
0.03), although the association with the BAS-G (median
5.0 vs. 3.6, P = 0.1) was not significant. The level of PC3
was also significantly higher in the high MMP group
(1.125 vs. -0.511, P < 0.0001). In addition, patients in
the high MMP group were more likely to be current
smokers than those in the low MMP group (36.5% vs.
17.9%, odds ratio 2.60, 95% CI 1.26 to 5.38, P = 0.01).
An increasing frequency of the high MMP group was
also found with increasing pack-year category (P trend =
0.001) (Table 8).
Discussion
In this study we analysed the serum levels of a large
panel of cytokines, chemokines, MMPs and TIMPs for
their association with measures of disease activity and
function in AS, using univariate and multivariate meth-
ods. We believe this is the largest study to date to exam-
ine such a large panel of biomarkers in AS. Our data
indicate that serum levels of MMPs in particular show
the strongest association with disease activity, as mea-
sured by the BASDAI. In contrast to some previous stu-
dies, we found that the strongest association was with
MMP-8 (or MMP-9) levels, rather than MMP-3 levels.
Importantly, we obtained similar findings using the
Luminex® system and ELISA methods. It is worth
noting that previously reported relationships between
MMP-3 levels and the BASDAI have often been based
on univariate correlations rather than multivariate
regression analysis, and correlations have not been con-
sistently found in all studies [9,14,16,17,23]. This may
reflect differences in the patient groups since it has also
been suggested that MMP-3 levels are higher in patients
with peripheral arthritis than those with axial disease
only [14,16,17], although this has not always been
observed [23]. The same may apply to IL-6, which has
also been shown to be higher in patients with peripheral
synovitis [5] but is not associated with the BASDAI in
all studies [14]. One of the limitations of the present
study was the absence of information on peripheral joint
disease in the patients studied.
The correlations of MMP-3 and IL-6 with disease
activity in some studies may be explained in part by the
association of these molecules with CRP levels. Like pre-
vious studies, we found correlations of MMP-3 and IL-6
with CRP levels - although we also found that MMP-2
and MMP-8 levels were independently associated in a
multivariate model containing MMP-3. IL-6 was not
associated in this model. Interestingly the association
with MMP-2 was negative, suggesting an anti-inflamma-
tory role for this MMP, which is consistent with other
studies in inflammatory arthritis [29,30].
The associations of MMP-8 and MMP-9 levels with
the BASDAI were not independent of each other, and
probably reflect involvement of the same pathway in the
release of these particular MMPs. MMP-8 (neutrophil
collagenase) is primarily produced by activated neutro-
phils, while MMP-9 is released mainly by neutrophils
and macrophages.
In the PCA, MMP-8 and MMP-9 are also associated
with CXCL8 and HGF (in the PC3 profile), both of
which have also been associated with neutrophil activa-
tion [31,32]. The association of the BASDAI with this
component may thus reflect a possible relationship
between disease activity and neutrophil activation in
AS. However, the biomarkers making up the PC3 pro-
file are also associated with aspects of angiogenesis
[33-35], although this may be linked also to an associa-
tion with neutrophil activation. For example, neutro-
phil-derived MMPs can promote neoangiogenesis
through release and activation of angiogenesis promo-
ters (for example, VEGF-A) from the extracellular
matrix [33]. Other studies in AS have shown a correla-
tion between VEGF levels and disease activity
Table 5 Multiple regression analysis showing baseline
association of PC3 (MMP-8, MMP-9, HGF, CXCL8) with the
BASDAI
Response variable (BASDAI)a
Independent variable Regression coefficient (SE) P value
Female 0.282 (0.128) 0.029
PC3 0.080 (0.027) 0.004
HGF, hepatocyte growth factor; MMP, matrix metalloproteinase; PC, principal
component; SE, standard error. aSquare root transformation of the Bath
ankylosing spondylitis disease activity index (BASDAI) was carried out to
achieve a normal distribution.
Table 6 Association between principal component 3 and pack-year category
Variable 0 pack years (n = 61 1 to 15 pack years (n = 37) 16 to 30 pack years (n = 17) > 30 pack years (n = 14) P (trend)a
PC3 -0.10 (1.80) 0.38 (1.17) 0.79 (1.21) 1.86 (2.51) < 0.0005
Mean (standard deviation) values are shown. PC, principal component. aLinear test for trend.
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[8,13,14], although we failed to find an association in
this study. Further work is needed to determine with
which particular aspects of the disease process the
markers associated with PC3 are most closely asso-
ciated. The association of PC3 with the BASDAI inde-
pendent of CRP suggests that it is not merely a
surrogate for systemic inflammation.
It is noteworthy that PC3 was also associated with
current smoking, and that a significant trend was seen
in relation to pack-year history. This appears to be lar-
gely due to associations with MMP-8 and MMP-9
levels, which have been shown in other studies to be
increased in smokers [36,37]. Hierarchical clustering
analysis also revealed an association between patients
with high MMP levels and current smoking, as well as
a quantitative relationship with pack-year history. All
of these data add weight to the idea that the PC3 pro-
file may reflect neutrophil activation, which is charac-
teristically found in smokers [38,39]. A number of
studies have indicated that smoking is associated with
increased disease activity, worse functional outcome
and poorer quality of life in patients with AS
[26,40-43]. Smoking has also been associated with
radiographic spinal progression in early axial spondy-
loarthritis independently of baseline radiographic
damage and elevated acute phase reactants [44]. These
associations may be explained in part by the increased
levels of MMPs (particularly MMP-8 and MMP-9) in
smokers. This association is suggested by the current
study since the association of the BASDAI and BASFI
with the pack-year category disappears when MMP-8
or MMP-9 levels are included in multivariate regres-
sion models along with pack-year history (data not
shown). Smoking may thus exacerbate the production
of neutrophil activation markers, but there also
appears to be an association of these markers with dis-
ease activity independent of smoking.
The association of disease activity with markers of
neutrophil and/or macrophage activation is interesting
in light of studies suggesting that the innate immune
pathway might be more important in axial spondyloar-
thritis than the adaptive immune response [45-48]. Infil-
tration of the synovium in axial spondyloarthritis by
macrophage subsets and neutrophils has been shown to
reflect global disease activity [47], while more recently
the role of IL-17 in axial spondyloarthritis has been
linked to increased numbers of IL-17+ neutrophils and
macrophage subsets in the subchondral bone marrow of
affected facet joints [48]. Other cell types such as CD3+
T cells, mast cells, B cells and natural killer cells pro-
vided little or no source of IL-17. The hypothesis that
the innate immune pathway, mostly mediated through
neutrophils, might be of greater relevance in AS inflam-
mation than the T-helper type 17 cell-mediated adaptive
immune response was therefore suggested. Such a sug-
gestion is in line with earlier studies that indicated sig-
nificant alterations in neutrophil function in patients
with AS [49-54]. These include alterations in chemo-
taxis, phagocytosis and superoxide radical anion genera-
tion. Priming of neutrophils has been suggested to be a
probable causative factor in the onset of AS, and
increased production of reactive oxygen species and
MMPs from these cells may lead to tissue damage in AS
[53]. Increased levels of advanced oxidation protein pro-
ducts, a novel oxidative stress marker of protein, have
been demonstrated in AS patients, and provide evidence
of oxidative stress mediated by neutrophil myeloperoxi-
dase-hypochlorous acid in these patients [54]. The cause
of increased neutrophil activation in AS is unclear -
although smoking is likely to have an exacerbating
effect, and cessation of smoking may therefore provide
one area for limited control of disease.
Conclusion
We have shown, using several methods of analysis, that
higher disease activity and worse function in patients
with established AS are associated with increased serum
levels of MMPs (particularly MMP-8 and MMP-9) and
cytokines/chemokines (HGF, CXCL8) associated with
neutrophil activation and/or angiogenesis. Serum MMP-
8 and/or MMP-9 levels are more strongly associated
with disease activity than MMP-3, and biomarker pro-
files containing high MMP-8/MMP-9 levels are asso-
ciated with smoking in AS.
Further work is needed to investigate the role of these
particular molecules in determining radiographic
Table 7 Levels of individual biomarkers comprising principal component 3 stratified by smoking status
Smoking status
Variable (pg/
ml)
Never (n = 61) Past (n = 56) Current (n = 40) P
valuea
Ever (n = 96) P
valueb
MMP-8 9,750 (4,767 to 14,668) 12,578 (6,906 to 26,066) 18,934 (10,792 to 28,988) 0.02 16,731 (8,001 to 27,241) 0.004
MMP-9 377,000 (258,488 to
607,190)
421,409 (248,758 to
627,056)
547,697 (344,692 to
802566)
0.01 466,416 (284,003 to
730,264)
0.04
CXCL8 27.0 (21.1 to 40.5) 30.0 (23.2 to 53.0) 34.0 (20.1 to 88.9) 0.4 31.9 (21.3 to 52.2) 0.2
HGF 421.7 (327.8 to 678.3) 430.3 (305.9 to 648.3) 408.4 (337.7 to 555.2) 1.0 427.1 (327.8 to 646.1) 0.9
HGF, hepatocyte growth factor; MMP, matrix metalloproteinase. aKruskal-Wallis test. bEver smoked versus never smoked (Mann-Whitney U test).
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Figure 1 Hierarchical cluster analysis of serum matrix metalloproteinase levels in patients with ankylosing spondylitis. Results are
displayed as a heat map and dendrogram in which the relative levels of matrix metalloproteinases (MMPs) are represented by shades of yellow/
red (high) and blue (low). Each row represents the MMP profile for an individual patient, each of which is represented by a number on the
vertical axis. Each column represents a different MMP (MMP-1, MMP-2, MMP-3, MMP-8 and MMP-9, left to right). C1, high MMP cluster; C2, low
MMP cluster.
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outcome in AS, and their potential use as markers of
response to therapy.
Additional material
Additional file 1: Table S1 presenting correlations between clinical
measures and biomarkers in ankylosing spondylitis patients at
baseline.
Additional file 2: Table S2 presenting correlations between clinical
measures and MMP-3 and MMP-8 levels measured by ELISA in
ankylosing spondylitis patients at baseline.
Additional file 3: Table S3 presenting alternative multiple
regression models showing variables associated with the BASDAI
and BAS-G at baseline.
Additional file 4: Table S4 presenting levels of individual
biomarkers comprising principal component 3 stratified by pack-
year category.
Additional file 5: Table S5 presenting a comparison of MMP levels
in patient clusters with low or high MMP levels as selected by
hierarchical cluster analysis.
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